Showing results (21-30 of 63) with videos related to
Sort By:
Pageof 7
International Medical Case Reports Journal|June 12, 2013
Obstructive jaundice at the initial presentation in small-cell lung cancerNobuaki Ochi, Nagio Takigawa, Masayuki Yasugi, et al.Thoracic Cancer|December 29, 2021
Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational studyTomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, et al.Thoracic Cancer|November 20, 2022
Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome studyDaijiro Harada, Tomoki Tamura, Kiichiro Ninomiya, et al.Cancer Science|June 21, 2012
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutationDaijiro Harada, Nagio Takigawa, Nobuaki Ochi, et al.Oncology Letters|November 20, 2024
Features of late local failure of early‑stage non‑small cell lung cancer treated with stereotactic body radiotherapyKenji Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, et al.Lung Cancer (Amsterdam, Netherlands)|December 2, 2019
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancerEiki Ichihara, Daijiro Harada, Koji Inoue, et al.Experimental Cell Research|November 22, 2021
Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cellsNozomu Nakagawa, Noriko Miyake, Nobuaki Ochi, et al.Journal of Cancer Research and Clinical Oncology|March 29, 2021
Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitorsNaofumi Hara, Eiki Ichihara, Daijiro Harada, et al.Lung Cancer (Amsterdam, Netherlands)|November 22, 2019
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203Yoko Tsukita, Akira Inoue, Shunichi Sugawara, et al.Cancer Immunology, Immunotherapy : CII|July 11, 2020
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitorsEiki Ichihara, Daijiro Harada, Koji Inoue, et al.Pageof 7